To provide the information your oncologist is not telling you or doesn't have the time to!
Stay Informed About the Latest Oncology Breakthroughs
Explore the forefront of oncological research with our “Research Advances” category. Discover cutting-edge studies, innovative treatments, and scientific insights into cancer. Stay up-to-date with the latest breakthroughs and advancements in the field of oncology to make informed decisions about your health or that of your loved ones. Dive into the world of scientific progress and gain a deeper understanding of how research is shaping the future of cancer care.
If you or a loved one is battling locally advanced or metastatic urothelial cancer (la/mUC), there’s groundbreaking news to share. On December 15, 2023, the Food and Drug Administration (FDA) gave the green light to a dynamic combination of treatments: enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda). This approval is especially significant for patients ineligible for …
On December 14, 2023, the FDA gave the green light to belzutifan (Welireg, Merck & Co., Inc.), offering new hope for individuals battling advanced kidney cancer. It’s like unlocking a powerful tool after trying different strategies. Understanding Belzutifan’s Power Against Kidney Cancer Imagine your body as a bustling city with the kidneys playing the role …
Empowering Hope: A Breakthrough in CLL/SLL Treatment On December 1, 2023, the Food and Drug Administration (FDA) delivered a beacon of hope by granting accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company). This approval is a significant stride in the treatment landscape for adults facing chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) …
On December 13, 2023, the Food and Drug Administration (FDA) achieved a significant breakthrough by granting approval to eflornithine (IWILFIN, USWM, LLC) for use in both adult and pediatric patients facing the challenges of high-risk neuroblastoma (HRNB). This groundbreaking decision marks the first-ever FDA approval of a therapy designed to reduce the risk of relapse …
In a groundbreaking move, the Food and Drug Administration (FDA) has granted approval for enzalutamide (Xtandi, Astellas Pharma US, Inc.) to address non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence. This significant development brings renewed hope for patients at high risk for metastasis. The Road to Approval: EMBARK Trial Insights In the EMBARK clinical trial …
Cancer screening has witnessed a transformative evolution, with technological advancements paving the way for more effective and less invasive methods. In this article, we will explore the integration of liquid biopsies as a groundbreaking approach to early cancer detection. This non-invasive method holds immense potential in detecting genetic alterations and circulating tumor DNA, ushering in …
The latest development in breast cancer treatment brings hope and progress. On November 16, 2023, the Food and Drug Administration (FDA) approved capivasertib, in combination with fulvestrant, for adult patients battling hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. This approval marks a significant step forward for …
This is a new modified TIL protocol developed by Obsidian Therapeutics now open for enrollment at the Orlando Health Cancer Institute. All information provided here are from public sources and the protocol details can be found here. Please reach out to Karin Donaldson if interest in seeking this trial. This current protocol is specific for …
by Sajeve Thomas, MD, Oncologist Biliary tract cancer (BTC), a rare and aggressive form of cancer affecting the bile ducts, gallbladder, and liver, has historically been challenging to treat. However, there is hope on the horizon with the recent FDA approval of pembrolizumab (Keytruda, Merck) in combination with chemotherapy. This groundbreaking development offers new possibilities …
On November 7, 2023, the Food and Drug Administration (FDA) made significant updates to the existing indication of pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. These changes come as part of the FDA’s commitment to advancing cancer treatment options, bringing …